Table 2.
M-CSF levels according to clinical features.
| Groups | N | M-CSF (pg/ml) | p |
|---|---|---|---|
| Vasculitis serotype | |||
| Anti-PR3 – vasculitis | 18 | 289.08 (197.36–622.47) | NS |
| Anti-MPO – vasculitis | 11 | 327.13 (159.49–432.75) | |
| Vasculitis phenotype | |||
| GPA | 18 | 289.08 (197.36–622.47) | NS |
| EGPA | 6 | 159.49 (107.71–325.95) | |
| MPA | 5 | 385.09 (327.13–480,41) | |
| Histological findingsa | |||
| Diagnostic renal biopsy | 8 | 460.61 (313.32–868.86) | NS |
| Diagnostic biopsy in non-renal tissues | 6 | 205.30 (121.00–284.99) | |
| Non-diagnostic biopsy | 7 | 231.75 (204.77–607.15) | |
| Urinary sediment in patients with renal involvement | |||
| Active | 3 | 1258.35 (251.77–581.72) | NS |
| Non active | 11 | 386.03 (792.74–1429.48) | |
| Presence of proteinuria in patients with renal involvement | |||
| Proteinuria present | 7 | 480.41 (383.97–970.69) | NS |
| Proteinuria absent | 7 | 271.90 (226.42–644.33) | |
| Pulmonary phenotypes | |||
| Alveolar haemorrhage | 3 | 231.65 (161.52–308.37) | NS |
| Nodular lesions without alveolitis | 11 | 386.03 (247.84–909.62) | |
a
In eight cases no biopsy was performed.